{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:41:04Z","timestamp":1787503264911,"version":"build-2736575974"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To evaluate the diagnosis, monitoring, and treatment of systemic lupus erythematosus (SLE) in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>A 63-question electronic survey was developed with the Canadian Rheumatology Association and others. Descriptive analyses of responses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Survey respondents (n = 175) reported varying practices in the diagnosis, monitoring, and treatment of SLE. Performance of laboratory investigations for diagnosis and monitoring varied, with 78% of responders performing them at least every 6 months. Validated measures of SLE disease activity and damage were not commonly used. Most common first-line agents besides steroids for induction therapy for class III or IV lupus nephritis included intravenous cyclophosphamide and mycophenolate mofetil. Antimalarial use was common, with 96% of respondents using these in active skin disease. Over 60% of respondents indicated that 80\u2013100% of their patients were taking antimalarials, while another 25% indicated they used these drugs in up to 80% of their patients. There were 71% of responders who reported completing frequent (6\u201312 mos) ophthalmology screening in patients taking antimalarials. Biologics were infrequently used. Responders were more likely to stop azathioprine and chloroquine than hydroxychloroquine in pregnant patients with SLE. Other aspects of routine care including vaccination and cardiovascular risk management varied considerably. The majority (80%) agreed that a dedicated multidisciplinary care team would improve SLE care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Considerable practice variation in SLE management was noted. This may help inform future recommendations for the diagnosis, monitoring, and treatment of SLE in Canada.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.171307","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T07:29:36Z","timestamp":1533108576000},"page":"1440-1447","source":"Crossref","is-referenced-by-count":17,"title":["Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada"],"prefix":"10.3899","volume":"45","author":[{"given":"Stephanie O.","family":"Keeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asvina","family":"Bissonauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Peschken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Urowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"2018112909390558000_45.10.1440.1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.20452\/pamw.432","article-title":"New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective","volume":"118","author":"Wallace","year":"2008","journal-title":"Pol Arch Med Wewn"},{"key":"2018112909390558000_45.10.1440.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117200"},{"key":"2018112909390558000_45.10.1440.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210960"},{"key":"2018112909390558000_45.10.1440.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.20628"},{"key":"2018112909390558000_45.10.1440.5","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu2024oa"},{"key":"2018112909390558000_45.10.1440.6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ced.12295","article-title":"The Systemic Lupus International Collaborating Clinics criteria have replaced the American College of Rheumatology guidelines for the diagnosis of systemic lupus erythematosus","volume":"39","author":"Stephenson","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"2018112909390558000_45.10.1440.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem233"},{"key":"2018112909390558000_45.10.1440.8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrrheum.2016.137","article-title":"The global burden of SLE: prevalence, health disparities and socioeconomic impact","volume":"12","author":"Carter","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2018112909390558000_45.10.1440.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"2018112909390558000_45.10.1440.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"2018112909390558000_45.10.1440.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"2018112909390558000_45.10.1440.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2018112909390558000_45.10.1440.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2018112909390558000_45.10.1440.14","first-page":"927","article-title":"Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG)","volume":"69","author":"Symmons","year":"1988","journal-title":"Q J Med"},{"key":"2018112909390558000_45.10.1440.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2018112909390558000_45.10.1440.16","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#"},{"key":"2018112909390558000_45.10.1440.17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/0961203317716788","article-title":"Practice patterns in longitudinal lupus care provision: patient and physician perspectives","volume":"26","author":"Kugasia","year":"2017","journal-title":"Lupus"},{"key":"2018112909390558000_45.10.1440.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7370.961"},{"key":"2018112909390558000_45.10.1440.19","doi-asserted-by":"publisher","DOI":"10.1177\/1062860610375107"},{"key":"2018112909390558000_45.10.1440.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080828"},{"key":"2018112909390558000_45.10.1440.21","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313490434"},{"key":"2018112909390558000_45.10.1440.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110686"},{"key":"2018112909390558000_45.10.1440.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101173240303"},{"key":"2018112909390558000_45.10.1440.24","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678919778"},{"key":"2018112909390558000_45.10.1440.25","unstructured":"Roche Pharmaceuticals . CellCept (mycophenolate mofetil) US prescribing information. [Internet. Accessed June 27, 2018.] Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050722s021,050723s019,050758s019,050759s024lbl.pdf"},{"key":"2018112909390558000_45.10.1440.26","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00198-015-3149-3","article-title":"Presentation and management of osteoporosis presenting in association with pregnancy or lactation","volume":"26","author":"Kovacs","year":"2015","journal-title":"Osteoporos Int"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:29:39Z","timestamp":1751761779000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,1]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.3899\/jrheum.171307"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171307","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}